Dxcover Limited, a clinical-stage diagnostics company pioneering Multi-Omic Spectral Analysis for early detection of multiple cancers, announced that Founder and newly announced CEO Matthew Baker, PhD, will be presenting at Biotech Showcase 2024. Prof. Baker will be presenting data from the company’s clinical studies in early detection of solid tumors.
Dxcover’s novel platform utilizes infrared spectroscopy and AI algorithms to provide Multi-Omic Spectral Analysis (MOSA) of blood serum. The company’s recently released data showed its algorithms could accurately detect stage I-IV cancer of multiple solid tumors and was published in the British Journal of Cancer and earned first prize as a poster in the Innovative Diagnostic Tools category at the European Society for Medical Oncology (ESMO) Congress 2023.
The company is currently advancing its test for brain cancer through multi-center European studies to obtain IVDR approval and embarking on a major prospective study in colorectal cancer and advanced adenoma early detection.
Also Read: Owkin enters collaboration agreement with MSD to develop AI-powered diagnostics for cancer
“Dxcover was founded to enable the earliest detection of cancer and we are thrilled to present at Biotech Showcase and share our science with potential collaborators, partners and investors,” said Prof. Baker. “We believe that the combination of Dxcover’s multi-omic spectral analysis and machine learning will lead to the greatest impact on patient recovery, lifespan and quality of life post diagnosis.”
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutics development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conferences take place each year in San Francisco during the course of one of the industry’s largest gatherings and busiest weeks.
“We are delighted that Dxcover will be joining us in San Francisco and presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime opportunity for life sciences entrepreneurs and investors to come together to discover the potential of innovative and technology that will drive the future of medicine.”
SOURCE: BusinessWire
